EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma”

EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor

Magnetic field tech captures the ‘song’ of a drug

EMulate Therapeutics Announces the Publication of Positive Pre-clinical Data Evaluating Pain Reduction via Delivery of Low and Ultra-low Radio Frequency Energy

EMulate Therapeutics Announces the Incorporation of A New Wholly Owned Subsidiary

EMulate Therapeutics Announces Promotion of Kyle Kingma to SVP, Finance, and GM, EMulate Subsidiaries - Corporate Update Announcement

It all begins with an idea.

EMulate Therapeutics Announces Issuance Of 41st Patent Covering The Design Of A Pediatric Therapeutic Device For Cancer And Other Health Indications

EMulate Therapeutics Announces the Incorporation of a Third Wholly Owned Subsidiary

EMulate Therapeutics Issues White Paper Detailing Magnetic Field Effects Via Low and Ultra-Low Radio Frequency Energy (ulRFE(R))

EMulate Therapeutics 2021 Year in Review - A Pivotal Year for the Company

EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries

EMulate Therapeutics Announces Issuance of Additional U.S. Patent Covering a Therapeutic Device for Cancer and Other Health Indications